The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape : Market Research Report

The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape

Published: Aug. 28, 2007 - 126 Pages

1 EXECUTIVE SUMMARY
2 INTRODUCTION TO BACTERIAL DISEASES: 2.1 Group A Streptococcus (GAS); 2.2 Group B Streptococcus (GBS); 2.3 Streptococcus pneumoniae; 2.4 Haemophilus Influenzae; 2.5 Neisseria Meningitidis; 2.6 Methicillin Resistant Staphylococcus Aurens (MRSA)
3 PATIENT DEMOGRAPHICS: 3.1 Group A Streptococcus (GAS) Patient Statistics; 3.2 Group B Streptococcus (GBS) Patient Statistics; 3.3 Streptococcus pneumoniae Patient Statistics; 3.4 Haemophilus Influenzae Patient Statistics; 3.5 Neisseria Meningitidis Patient Statistics; 3.6 MRSA Patient Statistics
4 KEY DRIVERS: 4.1 Drug Resistance; 4.2 New Treatments; 4.3 Patient Demographics; 4.4 Vaccines; 4.5 Potential for Clinical Success; 4.6 Indirect Cost Associated with Infectious Diseases
5 KEY RESISTORS: 5.1 Over-prescription; 5.2 Antibiotic Resistance Leading to Short Antibacterial Drug Lifecycles; 5.3 Acute Use of Antibiotics; 5.4 Generics; 5.5 Curative Therapies and Vaccines
6 THE MARKET: 6.1 The Global Anti-infective Market; 6.2 Market Segments; 6.3 Global Antibacterial Market; 6.4 The Major Players; 6.5 Market Trends
7 LEADING ANTIBACTERIAL DRUG CLASSES: 7.1 Aminoglycosides; 7.2 Carbapenems; 7.3 Cephalosporins; 7.4 Glycopeptide; 7.5 Ketolide; 7.6 Lipopeptide; 7.7 Macrolides; 7.8 Penicillins; 7.9 Oxazolidinones; 7.10 Pleuromutilins; 7.11 Quinolone
8 LEADING BRANDS: 8.1 Aminogylcoside Antibiotics; 8.2 Carbapenem Antibiotics; 8.3 Cephalosporins; 8.4 Glycopeptide Antibiotics; 8.5 Ketolide Antibiotics; 8.6 Lipopeptide Antibiotics; 8.7 Macrolide Antibiotics; 8.8 Oxazolidinone Antibiotics; 8.9 Penicillin Antibiotics; 8.10 Quinolone Antibiotics; 8.11 Pleuromutilin Antibiotics; 8.12 Other Antibiotics; 8.13 Global Antibacterial Sales Forecasts
9 FUTURE BRANDS: 9.1 Carbapenem Antibiotics; 9.2 Cephalosporin Antibiotics; 9.3 Dihydrofolate Reductase Inhibitor Antibiotics; 9.4 Glycopeptide Antibiotics; 9.5 Ketolide Antibiotics; 9.6 Macrolides; 9.7 Other Antibiotics; 9.8 Future Global Antibacterial Sales Forecasts
10 KEY COMPANY PROFILES: 10.1 Advanced Life Sciences; 10.2 Arpida Ltd; 10.3 Basilea Pharmaceutica AG; 10.4 Cerexa Inc.; 10.5 Cubist Pharmaceuticals, Inc.; 10.6 Targanta Therapeutics Corp.; 10.7 Theravance
APPENDIX 3: Acronyms
TABLES: Table 2.1 Infectious Disease Leading Worldwide Health Burden; Table 4.1 Potential for Clinical Success; Table 6.1 Historical Sales of Leading Antibiotics 2001-2005; Table 7.1 Different Classes of Antibacterial Agents; Table 8.1 Common Bacterial Infections; Table 8.2 Sales Forecasts of Leading Aminoglycosides US$mn 2005A - 2012E; Table 8.3 Sales Forecasts of Leading Carbapenems US$2005-2012E; Table 8.4 Approved Cephalosporin Antibiotics; Table 8.5 Sales Forecasts of Cephalosporins US$mn 2005-2012E; Table 8.6 Sales Forecasts of Leading Glycopeptides US$mn 2005A - 2012E; Table 8.7 Sales Forecasts of Ketolide Antibiotics US$mn 2005 - 2012E; Table 8.8 Clinical Efficacy of Cubicin Versus Comparator on Pathogens; Table 8.9 Sales Forecasts of Leading Lipopeptides US$mn 2005A - 2012E; Table 8.10 Sales Forecasts of Leading Macrolides US$m 2005A - 2012E; Table 8.11 Sales Forecasts of Leading Oxazolidinones US$m 2005A - 2012E; Table 8.12 Approved Penicillins; Table 8.13 Sales Forecasts of Leading Penicillins US$m 2005A - 2012E; Table 8.14 Approved Quinolone Antibiotics; Table 8.15 Sales Forecasts of Leading Quinolones US$m 2005A - 2012E; Table 8.16 Sales Forecasts of Leading Pleuromutilins US$m 2005A - 2012E; Table 8.17 Sales Summary of Leading Antibacterial Agents (US$m) 2005 - 2012E; Table 9.1 Antibiotics in Clinical Development; Table 9.2 DX-619 Potent Quinolone in Vitro Against Gram Positive Pathogens; Table 9.3: Sales Summary of New Antibacterial Agents (US$m) 2005 - 2012E
FIGURES: Figure 3.1 MRSA Among ICU Patients in the US, 1995-2004; Figure 6.1 Global Anti-Infective Market 2006; Figure 6.2 Global Anti-Infective Market 2015; Figure 6.3 Antibacterial Sales Split - Drug Class Split 2006; Figure 6.4 Cephalosporin Antibiotics - Leading Drugs 2006; Figure 6.5 Macrolide Antibiotics - Leading Drugs 2006; Figure 6.6 Penicillin Antibiotics - Leading Drugs 2006; Figure 6.7 Quinolone Antibiotics - Leading Drugs 2006; Figure 6.8 Other Antibiotics - Leading Drugs 2006; Figure 6.9 The Major Players 2006; Figure 6.10 The Major Players 2012; Figure 6.11 Antibacterial Agents - Drug Class Split 2012; Figure 7.1 Site of Action of Leading Antibacterial Agents; Figure 9.1 Number of Drugs in Development to Treat Infectious Diseases; Figure 9.2 Schematic of Drug-resistant Pathogens and Market Opportunities; Figure 9.3 DX-619 Effective in Severe Infection Models Potent Quinolone in Vitro Against Gram Positive Pathogens; Figure 9.4 DC-159a Effective in Severe RTI

Abstract

The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.

Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance. In addition, a number of new drug classes such as dihydrofolate reductase inhibitors (DHFR) are under evaluation which are effective in multi drug resistant organisms.

This report examines each of the antibacterial classes in turn, assessing the market potential and application in hospital and community-acquired infections.

The following product classes are analyzed in this report:

aminoglycosides
carbapenems
cephalosporins
dihydrofolate reductase inhibitors
glycopeptides
ketolides
lipopeptides
macrolides
penicillins
oxazolidinones
pleuromutulins
quinolones

The report assesses the overall antibacterial market, key classes and the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation and by leading players and their products and analyzes market trends.

The report also examines promising pipeline products and their potential impact on the prescription of current and new antibacterial agents and the future of the antibacterial market.

Key Features of this report:

Overview of the antibacterial market, including the main infectious agents, therapeutic drug classes and key players.
In-depth analysis of different classes of antibacterial agents, including leading antibacterial agents and a summary of leading brands within each class.
Comprehensive facts and figures for the antibacterial market, including main players and drug class break-downs.
Future trends in the antibacterial marketplace, driven by drug resistance and patient demographics.
Outlook for the antibacterial market, including the emergence of novel therapies and the impact of generics.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape

Table of Contents

Abstract